Drugs / SW-682
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06251310 | Jul 2024 → Jan 2027 expected | malignant mesothelioma | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SW-682 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06251310 ↗ |
| Route | Oral | “administered orally” NCT06251310 ↗ |